Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival

Introduction Lung cancer is the most common cause of cancer death in the world, and the most common type is non‐small‐cell lung cancer (NSCLC). At present, surgical resection, chemotherapy, and radiation therapy are the main treatments for patients with NSCLC, but unfortunately outcome remains unsat...

Full description

Saved in:
Bibliographic Details
Published in:The clinical respiratory journal 2015-07, Vol.9 (3), p.297-304
Main Authors: Araz, Omer, Ucar, Elif Yilmazel, Meral, Mehmet, Yalcin, Aslıhan, Acemoglu, Hamit, Dogan, Hasan, Karaman, Adem, Aydin, Yener, Gorguner, Metin, Akgun, Metin
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - mortality
Case-Control Studies
Class I and II HLA alleles
Female
Gene Frequency
Histocompatibility Antigens Class I - genetics
Histocompatibility Antigens Class II - genetics
Histocompatibility Testing
Humans
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - mortality
Male
Middle Aged
response to chemotherapy
survival
Survival Rate
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Lung cancer is the most common cause of cancer death in the world, and the most common type is non‐small‐cell lung cancer (NSCLC). At present, surgical resection, chemotherapy, and radiation therapy are the main treatments for patients with NSCLC, but unfortunately outcome remains unsatisfactory. Objectives This study aimed to determine whether Class I and II histocompatibility leukocyte antigen (HLA) alleles are related with response to chemotherapy and survival of lung cancer. Methods A total of 65 NSCLC patients (56 men and 9 women, mean age 58.4 ± 11 years) were included in the study. Patient groups were compared with a control group of 88 unrelated healthy kidney or bone marrow donors in order to clearly identify susceptible and protective HLA alleles in lung cancer. Target lesions and tumor response were assessed using the Response Evaluation Criteria for Solid Tumors (RECIST) guidelines. Results were classified into two groups: complete–partial response and stable–progressive disease. Results We found that expression of HLA‐A32, HLA‐B41, HLA‐B57, HLA‐DRB1*13, and HLA‐DQ5 were more frequent in the complete and partial response groups to chemotherapy than in the control group. The frequency of HLA‐A11, HLA‐A29, HLA‐BW6, HLA‐CW3, HLA‐DR1*1, and HLA‐DRB1*3 were determined to be higher in the stable and progressive disease groups taking chemotherapy than in the control group. Additionally, expressions of HLA‐A2 and HLA‐B49 were statistically related with 5‐year survival. Conclusion Our results suggested that expressions of HLA‐BW6 and HLA‐DRB1*13 alleles may be predictable markers for response to chemotherapy in lung cancer patients.
ISSN:1752-6981
1752-699X
DOI:10.1111/crj.12143